MX2009007368A - Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1). - Google Patents

Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1).

Info

Publication number
MX2009007368A
MX2009007368A MX2009007368A MX2009007368A MX2009007368A MX 2009007368 A MX2009007368 A MX 2009007368A MX 2009007368 A MX2009007368 A MX 2009007368A MX 2009007368 A MX2009007368 A MX 2009007368A MX 2009007368 A MX2009007368 A MX 2009007368A
Authority
MX
Mexico
Prior art keywords
trem
activity
expression
patient
subject
Prior art date
Application number
MX2009007368A
Other languages
English (en)
Inventor
Lih-Ling Lin
David Winkler
Cara Williams
Jeffrey L Feldman
Debra D Pittman
Kuaijun
Ken Dower
Moitreyee Chatterjee-Kishore
Scott Alan Jelinsky
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009007368A publication Critical patent/MX2009007368A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Abstract

La presente invención proporciona métodos de tratamiento de enfermedades/trastornos inflamatorios en un sujeto, al inhibir/antagonizar la expresión/actividad/transducción de señal de TREM-1 y/o la expresión y/o actividad de DAP12/TyroBP. También se incluyen los métodos de detección de la presencia de la enfermedad inflamatoria en un sujeto o una muestra obtenida de ello, en donde una expresión o actividad incrementada es indicativa de la enfermedad inflamatoria. La presente invención proporciona además métodos para la evaluación de la eficacia de un agente modulador de TEM-1 administrado a un paciente por la detección de los niveles de fosfoproteína 1 secretada (SPP1) y/o uno o más de otros biomarcadores en el paciente o en una muestra del paciente.
MX2009007368A 2007-01-16 2008-01-16 Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1). MX2009007368A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88080407P 2007-01-16 2007-01-16
US90426407P 2007-02-28 2007-02-28
US92313107P 2007-04-11 2007-04-11
US168707P 2007-11-02 2007-11-02
PCT/US2008/000629 WO2008088849A2 (en) 2007-01-16 2008-01-16 Inflammation treatment, detection and monitoring via trem-1

Publications (1)

Publication Number Publication Date
MX2009007368A true MX2009007368A (es) 2009-07-16

Family

ID=39560886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007368A MX2009007368A (es) 2007-01-16 2008-01-16 Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1).

Country Status (9)

Country Link
US (1) US20080247955A1 (es)
EP (1) EP2121750A2 (es)
JP (1) JP2010516678A (es)
CN (1) CN101687916A (es)
AU (1) AU2008205538A1 (es)
BR (1) BRPI0806680A2 (es)
CA (1) CA2675583A1 (es)
MX (1) MX2009007368A (es)
WO (1) WO2008088849A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084082A1 (en) * 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP2011093806A (ja) * 2008-02-20 2011-05-12 Tokyo Medical & Dental Univ 膠原病の予防・治療剤
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
JP5499405B2 (ja) * 2010-06-02 2014-05-21 学校法人 聖マリアンナ医科大学 再発性多発軟骨炎の検査方法およびそれに用いられる検査キット
ES2750209T3 (es) * 2012-02-15 2020-03-25 Novo Nordisk As Anticuerpos que se unen a y bloquean al receptor desencadenante expresado en células mieloides-1 (TREM-1)
EP3196214B1 (en) * 2012-02-15 2019-07-31 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
SI2814842T1 (sl) 2012-02-15 2018-10-30 Novo Nordisk A/S Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
CA2904099A1 (en) 2013-03-15 2014-09-18 The Broad Institute, Inc. Dendritic cell response gene expression, compositions of matters and methods of use thereof
EP2835641A1 (en) * 2013-08-09 2015-02-11 Inotrem Methods and kits for predicting the risk of having a cardiovascular disease or event
AR099856A1 (es) * 2014-03-27 2016-08-24 Genentech Inc Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
JP6738316B2 (ja) 2014-07-17 2020-08-12 ノヴォ ノルディスク アクティーゼルスカブ 粘度を低下させるためのｔｒｅｍ−１抗体の部位特異的変異誘発
US11213598B2 (en) 2015-11-12 2022-01-04 The Board Of Trustees Of The Leland Stanford Junior University Labeled probe and methods of use
FR3044325B1 (fr) * 2015-12-01 2019-05-03 Biomerieux Procede d'evaluation du risque de complications chez les patients qui presentent un syndrome de reponse inflammatoire systemique (sirs)
CN106053831A (zh) * 2016-06-05 2016-10-26 潘时辉 一种用于自身免疫病检测的试剂盒
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
SI3601358T1 (sl) * 2017-08-03 2023-10-30 Alector Llc Protitelesa ANTI-TREM2 in načini njihove uporabe
WO2019087200A1 (en) * 2017-11-06 2019-05-09 Rambam Med-Tech Ltd. Prognostic methods for anti-tnfa treatment
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
CN108752482B (zh) * 2018-06-12 2019-04-30 南京卡提医学科技有限公司 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用
EP3836951A1 (en) 2018-08-13 2021-06-23 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
CN109833480B (zh) * 2019-03-22 2021-09-07 中国科学院上海巴斯德研究所 靶向nk细胞免疫检查点治疗感染性疾病的方法
EP3946349A4 (en) * 2019-04-03 2023-05-24 The Scripps Research Institute TREM-1 INHIBITION METHOD
EP3999541A1 (en) * 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
CN111157741B (zh) * 2019-12-30 2022-08-16 广州市妇女儿童医疗中心 髓系细胞触发受体1在制备胃炎诊断或治疗试剂中的应用及试剂盒
CN111437380A (zh) * 2020-05-25 2020-07-24 南通大学 Trem-2在监测血吸虫病肝纤维化进程的方法及应用
CN112266956B (zh) * 2020-11-12 2021-09-10 四川大学 Map3k8检测试剂在制备牙髓炎筛查试剂盒及抑制剂在制备治疗牙髓炎的药物中的用途
CA3224001A1 (en) * 2021-06-25 2022-12-29 Amgen Inc. Treatment of cardiovascular disease with trem-1 antigen binding proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5296347A (en) * 1991-02-08 1994-03-22 Ciba Corning Diagnostics Corp. Bridge immunoassay
JP2004522742A (ja) * 2000-12-08 2004-07-29 ベイラー　カレッジ　オブ　メディシン 免疫応答の改変において使用するためのｔｒｅｍ−１スプライス改変体
SI1507556T1 (sl) * 2002-05-02 2016-10-28 Wyeth Holdings Llc Konjugati kaliheamicinski derivat-nosilec
AR050642A1 (es) * 2004-09-10 2006-11-08 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
NZ552065A (en) * 2004-11-29 2008-04-30 Bioxell Spa Peptides derived from the TREM-1 protein that act as antagonists of the TREM-1 protein and have applications in the treatment of sepsis and septic shock
GB0426146D0 (en) * 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200728718A (en) * 2006-01-20 2007-08-01 Nat Defense Medical Ct Biomarkers for diagnosis of crescentic glomerulonephritis
US20070224638A1 (en) * 2006-03-27 2007-09-27 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections

Also Published As

Publication number Publication date
WO2008088849A9 (en) 2009-04-09
CN101687916A (zh) 2010-03-31
JP2010516678A (ja) 2010-05-20
EP2121750A2 (en) 2009-11-25
AU2008205538A1 (en) 2008-07-24
US20080247955A1 (en) 2008-10-09
WO2008088849A2 (en) 2008-07-24
WO2008088849A3 (en) 2008-09-18
BRPI0806680A2 (pt) 2015-06-16
CA2675583A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
MX2009007368A (es) Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1).
Mai et al. Calcitonin gene-related peptide (CGRP) in autonomic cardiovascular regulation and vascular structure
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
Siuda et al. Social isolation-induced epigenetic changes in midbrain of adult mice
WO2011133477A3 (en) Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
EP2365335A3 (en) Diagnostic method
NO20081595L (no) Raf-inhibitorforbindelser og fremgangsmater for anvendelse derav
WO2011057003A3 (en) Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
ATE524565T1 (de) Transkriptionsuntreue, nachweis und verwendungen davon
WO2006133287A3 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
EP1756571B8 (en) Real time method of detecting acute inflammatory conditions
WO2010036960A8 (en) Methods for treating, diagnosing, and monitoring lupus
DE602004024539D1 (de) Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
DE502006008028D1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
WO2007050588A3 (en) Systems and methods for characterizing conditions of organs for transplantation
EP3839068A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
ATE433115T1 (de) Timp-2 als ziel/marker des versagens von beta- zellen
GB0914209D0 (en) Agents and methods for early diagnosis and monitoring of alzheimers disease and other neurological disorders
Kuo et al. The role of urodynamic study in evaluation of interstitial cystitis/painful bladder syndrome
Yeh et al. The circadian rhythm of blood pressure is masked by postural changes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal